
Introduction
We have many patients and friends who suffer from polycystic ovarian syndrome (PCOS), now referred to as polyendocrine metabolic ovarian syndrome (PMOS).1,2 This name change signifies the progress in awareness surrounding this condition and the complex pathophysiology and sequelae involved. It also points to the fact that this diagnosis is not based on a problem with the ovaries alone. It is secondary to hormonal abnormalities in hormones testosterone, estrogen, FSH, LH, and insulin that leads to an array of symptoms and diverse presentations.
Let’s first break down some basics of the menstrual cycle. First, GnRH or gonadotropin releasing hormone is produced from the hypothalamus in the brain, which recruits FSH, or follicle-stimulating hormone secretion from the pituitary gland, which tells the ovarian granulosa cells to recruit a follicle for ovulation and to convert androgens (testosterone) to estradiol (estrogen). LH or luteinizing hormone also comes from the pituitary, triggered by GnRH, to cause rupture of that follicle from the ovary, into the fallopian tube, and finally into the uterus with hopes of being fertilized. LH also functions to promote androgen production from the ovarian theca cells. The hypothalamus relies on estrogen levels in the blood from the ovary to know when to send out GnRH to wake up the pituitary gland to release FSH and LH. These hormones share a communication system that was titled the HPO axis (hypothalamic-pituitary-ovarian axis). In PMOS, the communication between the ovaries and brain gets muffled, like bad cell phone connection, when there are abnormal levels of estrogen, testosterone, and insulin circulating. The dance-like rhythm these hormones need to be secreted at predictable intervals and promote one dominant egg to ovulate is disrupted.

Additionally, 50-70% of women with PMOS have some degree of insulin resistance.3 In all bodies, insulin, a hormone produced by the pancreas, is released in response to increased sugar in the blood to cause your cells to take up sugar for energy production. There are insulin receptors on the walls of your cells prepared to take in glucose when insulin is bound to the receptors. Insulin resistance occurs when the cells’ receptors become resistant to the release of insulin, leading to more insulin production from the pancreas in hopes of uptaking more sugar and thus producing more energy. This cycle continues, and the problem worsens without proper treatment. This can ultimately lead to increased risk of diabetes, high cholesterol, high blood pressure, and cardiovascular disease.3 Insulin resistance also further exacerbates production of testosterone, estrogen, as well as reducing a hormone from the liver called sex hormone binding globulin (SHBG). SHBG binds to free testosterone in the blood, so when it is low this allows testosterone levels to remain high.
PMOS affects about anywhere from 10-15% of the population and is progressively increasing,4 and yet the cause of PMOS is still being investigated. It is thought to originate from a variety of factors such as genetics (primarily), environmental exposures, and potentially other unknown causes. Thus, if you suffer from PMOS, this is NOT your fault. You are not broken. You have not messed up your body permanently because you ate a little too much fast food in high school or were on the birth control pill. Your body is doing its best to compensate for the hormonal chaos this condition causes. Your body is on your team.
Signs and Symptoms
PMOS has annoying symptoms at best, and at worst: infertility, a complicated pregnancy, pregnancy loss, increased risk of metabolic syndrome and cardiovascular disease, increased risk of endometrial (uterine) cancer, and increased risk of anxiety, depression, and eating disorders. The signs of PMOS include but are certainly not limited to:5
- abnormal hair growth on the chin/neck/back/chest
- hair loss on the scalp, balding
- acne on the face/chest/back
- weight gain
- irregular menstrual cycles
- Mental illness such as anxiety, depression, or eating disorders
Diagnosing PMOS
PMOS is diagnosed with the Rotterdam criteria (created in 2003), if you met 2 out of 3 conditions, you received the diagnosis. The criteria was updated in 2023, and now you do not need polycystic ovaries on ultrasound to confirm the diagnosis.6
- Hyperandrogenism AKA signs of high testosterone (hirsutism or abnormal hair growth, acne, hair loss) or high serum (blood) free testosterone or DHEA
- Irregular menstrual cycles or anovulation – clinically defined as menstrual cycles < 21 days or > 35 days apart or less than 8 total periods per year
- polycystic ovaries on ultrasound, with generally > 10 per section or > 20 follicles total in one ovary OR ovarian fluid volume > 10 mL in one ovary OR increased anti-Mullerian hormone (AMH) blood level
- AMH is a hormone produced by the ovarian granulosa cells. It indicates ovarian reserve and is often utilized for fertility testing. Since many women with PMOS have increased recruitment of ovarian follicles, the AMH level is typically high
When your healthcare provider is seeking to diagnose PMOS, they will likely ask you about your symptoms, do a basic physical exam, order some labs and potentially a pelvic ultrasound.
Treatment Approaches
There are a variety of ways to approach managing PMOS. Depending on the provider you see, they may approach its management differently. The management will also depend on whether you are trying to conceive or wanting to conceive in the future.
- Nonhormonal Management and Lifestyle Changes
- Lifestyle interventions
- There is emerging research identifying the best ways to fuel your body and exercise for this condition. There is no specific diet proven to be most effective for PMOS. However, In general, research suggests the best ways to fuel your body include whole foods, low glycemic index (GI), high protein, high fiber diet.7,8 This is not very surprising, given this is a great way to fuel your body in general! It is shown that specifically a hearty, high protein balanced breakfast helps keep blood sugar levels more stable throughout the day than in those who skip breakfast or eat a subpar breakfast.8-10 Protein intake suppresses ghrelin (our hormone that tells you that you’re hungry) significantly longer than glucose, providing prolonged satiety, while carbohydrate ingestion alone stimulates cortisol (stress hormone) and DHEA (androgenic hormone).11 In general, striving for protein to be 30-40% of your diet.12,13 This is often achieved by having a protein source (yogurt, eggs, bacon/sausage, whey protein powder, etc) at breakfast and an animal protein source at least the size of your palm at lunch and dinner.
- Carbohydrates remain an important part of the diet, especially for quick energy prior to a workout. However, there are different types of carbohydrates, simple and complex. Simple carbs are things like baked goods, donuts, white bread, white rice, and simple sugars. These carbohydrates consumed alone spike blood sugar, which can exacerbate insulin resistance and its associated inflammation.14 It can also lead to a reactive hypoglycemia where blood sugar falls due to a compensatory spike in insulin, leading to cortisol and androgen hormone release.15,16 Complex carbohydrates include fruit, berries, whole grains, quinoa, starchy vegetables, legumes. Complex carbohydrates contain fiber which slows the release of glucose into the bloodstream. Balancing carbohydrates with protein, fiber, and fat are key to stabilizing blood sugar and keeping you satisfied longer as well as promoting improvements in insulin resistance, weight, and release of inflammatory markers.16
- An important consideration as we discuss dietary guidance for managing PMOS is that women with this condition have a 4-fold increased risk of disordered eating,17 and thus it is important to take an individualized approach in this discussion and catering a nutrition discussion toward goals of a healthy mind and body. Please inform your healthcare provider of any history of or current disordered eating patterns so they can provide the best care to you.
- Lifestyle interventions
- Medical Management
- Combined oral contraceptive pill (COCP)
- This is obviously not an option if you are trying to conceive. The birth control pill can be advantageous for PMOS because it increases insulin levels, increases a protein called sex hormone binding globulin (SHBG) which binds to and thus reduces free testosterone in the bloodstream.18 The progestin component of the pill also acts by decreasing LH hormone secretion, helping to minimize hormone output from the ovaries and manage estrogen and testosterone levels.18 These effects lead to decreased symptoms of hirsutism and acne. Additionally, because you have an induced period every month, it protects the uterine lining by causing it to shed every 28 days. It’s important to understand the birth control pill does not “regulate your cycle” per se but takes over your cycle to mimic a regular cycle. It has many benefits for PMOS, but does not treat or cure this condition and should not be described that way. Furthermore, some individuals experience mood symptoms that exacerbate mental health struggles, low libido or sexual desire, vaginal dryness, or rarely, weight changes, or blood clots.18 The progestin component of birth control pills is variable, as there are numerous forms of progestogens. Progestin is a synthetic form of the hormone progesterone. The different types vary slightly in structure and have different profiles based on androgen activity, promoting or reducing bleeding, and clotting risk. The progestins with the most anti-androgenic activity are generally the newer higher class progestins which increase SHBG, reduce testosterone, and are therefore best for symptoms of hirsutism.19 In order of most anti-androgenic to least include cyproterone acetate, drospirenone, desogestrel, norgestimate, and levonorgestrel.19,20 However, it is important to note that the more anti-androgenic progestins generally have higher clot risk.19,20
- A progestin only birth control, specifically drospirenone (brand name Slynd), is a reasonable alternative to a COCP for PMOS, as it is found to inhibit production of androgens from the adrenal glands and ovaries, competes with the peripheral androgen receptors, reduced the hormone LH, and inflammatory markers.21 The “mini pill” or other lower dose progestin-only birth control pills do not possess the same benefits for PMOS.
- Progesterone withdrawal medication
- If you are not on birth control, and do not have regular cycles despite changes you have made in your lifestyle, or in addition to metformin or inositol, your provider may give you medroxyprogesterone acetate (a synthetic form of progesterone) or micronized progesterone, a bioidentical progesterone, to take for about 5-10 days if you have not had a menstrual cycle in the past 3 months. This is to protect your uterine lining (endometrium) from becoming too thick, which can be a risk for abnormal cell growth that can increase the risk of endometrial cancer.22
- Metformin
- Metformin is a medication prescribed by a healthcare provider that helps to improve blood sugar and insulin resistance. It acts as an insulin sensitizer through enhanced uptake of glucose in skeletal muscle, reduced fat breakdown into sugar, and stimulation of GLP-1
- Benefits of metformin for individuals with PMOS include reductions in total testosterone and AMH, menstrual cycle regularity, improved fasting insulin, and possible reduction in cardiovascular risk. However, combined oral contraceptives continue to be the first line medication for managing symptoms of acne and hirsutism in PMOS24
- Metformin may increase rates of pregnancy and live birth rates, especially when used with ovulation induction medication.26
- Side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, decreased absorption of nutrients such as vitamin B12.26,27 Therefore you may consider optimizing intake of nutrients like calcium and vitamin B12 through whole food sources or supplementation.
- In a study comparing metformin to the birth control pill, they found the birth control may be more effective than metformin in improving hirsutism symptoms with less of the gastrointestinal side effects from metformin.28,29
- Anti-androgen medications
- Spironolactone
- This is a medication that acts as an androgen antagonist through binding to androgen receptors and reducing production of androgens from the adrenal glands and ovaries. This leads to reduced symptoms of hirsutism including acne, terminal hair growth on the chin or chest, as well as possible menstrual cycle regulation due to less hormonal disruption. It is often combined with oral contraceptives.23,30 Because of its activity on another hormone called aldosterone, it has important side effects such as dizziness, low blood pressure, and increased potassium levels that should be discussed with your healthcare provider.
- Spironolactone
- GLP-1 agonists
- Glucagon-like peptide-1 agonists, or GLP-1 agonists, are medications often given for weight loss and diabetes. However, there are numerous other indications being researched. GLP-1 is a hormone in the gut that stimulates insulin secretion from the pancreas. They are not formally recommended for PMOS management but are a suitable adjunct to lifestyle intervention. Evidence thus far has shown benefits including menstrual regularity, spontaneous pregnancy, reduced testosterone levels, and weight loss.26,31 While emerging data regarding its safety in pregnancy is promising, it is still recommended to stop the medication when actively trying to conceive or if you become pregnant.32
- They are available as injections or oral medications
- Side effects of GLP-1 agonists include nausea, vomiting, early satiety, constipation, abdominal pain, dizziness
- Combined oral contraceptive pill (COCP)
- Supplements for PMOS
- Inositol
- Inositol, or you may hear it as myoinositol, is a natural sugar alcohol that assists in cellular functions in all our cells. Inositols naturally occur as 9 stereoisomers, with the most abundant being myoinositol (MI) and D-chiro-inositol (DI). It is a supplement, with no prescription needed. In the ovary, myoinositol is involved in energy utilization and follicle-stimulating hormone (FSH) signaling, whereas DI controls glycogen (stored energy) synthesis and insulin-induced androgen synthesis.33,34 They are found in many fruits like prunes and cantaloupe, liver, nuts, beans, seeds, and whole grains. Inositol acts as an “insulin sensitizer” helping insulin to enter into cells upon stimulus from the glucose load that comes after meals. In studies, it has shown to be noninferior AKA just as good as metformin at regulating menstrual cycles, without the negative gastrointestinal side effects.35 It acts by reducing testosterone levels and increasing SHBG, but data shows limited benefit for reducing symptoms of hirsutism.35 Overall, these effects have been shown to help many women with PMOS ovulate regularly, but data is mixed on whether it truly helps with rates of pregnancy or miscarriage prevention.36
- Vitamin D
- Vitamin D3, active vitamin D, is produced in the body through a complex process beginning in the skin from exposure to UVB sunlight. The liver metabolized vitamin D3 synthesized in the skin as well as orally ingested vitamin D2 and D3. The final conversion step takes place in the kidneys where the active form 1,25-dihydroxyvitamin D is synthesized to regulate calcium and phosphate levels and bone metabolism.37 Vitamin D plays a significant role as an antioxidant, reducing oxidative stress and inflammation in the body, and it helps to mitigate the harmful effects of reactive oxygen species (ROS). Evidence shows many women with PMOS, along with the population in general, have vitamin D deficiency or insufficiency.38 Findings from various clinical trials have shown that vitamin D supplementation in women with PMOS helps to improve insulin sensitivity, glucose metabolism, and lipid profiles.39
- Omega 3 fatty acids (DHA/EPA)
- Omega 3 fatty acids come in several forms: ALA, DHA, and EPA. ALA is found in plant based sources such as chia seeds, flaxseed, walnuts. DHA and EPA are found in fish oil supplements or whole food sources like salmon, sardines, oysters, trout, enriched eggs, and algae oil. Unfortunately, the conversion process from ALA to DHA/EPA in our bodies is inefficient, and a very modest amount is truly converted and utilized. The reason this is important is that DHA and EPA hold the benefits for brain health, modulating lipid levels, as well as the additional nutritional benefits for pregnancy. Studies show omega 3 fatty acids or fish oil can reduce inflammatory markers and triglyceride levels,40 as well as testosterone levels, cholesterol levels, and improve insulin resistance.41
- Other minerals, vitamins, or herbs that have been studied with positive benefits for PMOS, that need more research:42-52
- Coenzyme Q10 (active form ubiquinol)
- Chromium picolinate (CrP)
- Cartinine
- N-acetylcysteine (NAC)
- Calcium
- Melatonin
- Probiotics
- Vitamin E
- Berberine
- And even herbal medicine:
- Curcumin (found in turmeric)
- Cinnamon
- Sage
- Fennel
- Pomegranate juice
- Infertility and Ovulation Induction
- If you have PMOS and have been trying to conceive for longer than 6 months to a year, your healthcare provider may recommend an ovulation induction medication: letrozole (brand name Femara) or clomiphene citrate (brand name Clomid). These medications act by either reducing circulating levels of estrogen (letrozole) or competing with the estrogen binding site in the hypothalamus and pituitary gland (clomid).53 The hypothalamus senses estrogen levels are low, which causes your brain to release FSH and LH, inducing a timed ovulation. For PMOS, letrozole is considered the first line ovulation induction medication as it has higher rates of both ovulation and pregnancy rates.23 These medications are generally well tolerated however clomid users may experience symptoms similar to menopause, like hot flashes and night sweats, while letrozole users may have more fatigue and dizziness.54 Both medications carry a small increased risk of twins or multiple pregnancy rate, about 5-10%.53
- Inositol
While this blog aims to be a thorough overview regarding current research in PMOS, it is not comprehensive of all the clinical data or all the expert opinions regarding this condition. If you have questions regarding this condition or have concerns you may have PMOS, consult a healthcare provider.
Best,
The PA Sisters
Disclaimer: this is not medical advice, but for informational and educational purposes only. Please consult your medical provider for unique medical guidance tailored to you.
References
- Teede H, Khomami M, Morman R et al.
Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet,2026;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext - Refaey M, Er A, Silverstone L, et al. Polyendocrine metabolic ovarian syndrome. Reference article, Radiopaedia.org (Accessed on 18 May 2026) https://doi.org/10.53347/rID-4620
- Stańczak, N. A., Grywalska, E., & Dudzińska, E. (2024). The latest reports and treatment methods on polycystic ovary syndrome. Annals of Medicine, 56(1). https://doi.org/10.1080/07853890.2024.2357737
- Prevalence of Polycystic Ovary Syndrome: A Global and Regional Systematic Review and Meta-Analysis.Human Reproduction Update. 2026. Neven ACH, Forslund M, Ranasinha S, et al
- Anju E Joham, Chau Thien Tay, Joop Laven, Yvonne V Louwers, Ricardo Azziz, Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome, The Journal of Clinical Endocrinology & Metabolism, Volume 110, Issue 7, July 2025, Pages e2298–e2308, https://doi.org/10.1210/clinem/dgae910
- Dason ES, Koshkina O, Chan C, Sobel M. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024 Jan 28;196(3):E85-E94. doi: 10.1503/cmaj.231251. Erratum in: CMAJ. 2024 Mar 3;196(8):E269. doi: 10.1503/cmaj.240216. Erratum in: CMAJ. 2024 Mar 17;196(10):E351. doi: 10.1503/cmaj.240303. PMID: 38286488; PMCID: PMC10833093.
- Gautam, R., Maan, P., Jyoti, A., Kumar, A., Malhotra, N., & Arora, T. (2025). The Role of Lifestyle Interventions in PCOS Management: A Systematic Review. Nutrients, 17(2), 310. https://doi.org/10.3390/nu17020310
- Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, Frearson M, Thondan M, Stepto N, Teede HJ. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013 Apr;113(4):520-45. doi: 10.1016/j.jand.2012.11.018. Epub 2013 Feb 16. PMID: 23420000.
- Sørensen LB, Søe M, Halkier KH, Stigsby B, Astrup A. Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome. Am J Clin Nutr. 2012 Jan;95(1):39-48. doi: 10.3945/ajcn.111.020693. Epub 2011 Dec 7. PMID: 22158730.
- Jakubowicz D, Barnea M, Wainstein J, Froy O. Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome. Clin Sci (Lond). 2013 Nov;125(9):423-32. doi: 10.1042/CS20130071. PMID: 23688334.
- Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Am J Clin Nutr. 2007 Mar;85(3):688-94. doi: 10.1093/ajcn/85.3.688. PMID: 17344488.
- Sørensen LB, Søe M, Halkier KH, Stigsby B, Astrup A. Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome. Am J Clin Nutr. 2012 Jan;95(1):39-48. doi: 10.3945/ajcn.111.020693. Epub 2011 Dec 7. PMID: 22158730.
- González-Salazar LE, Pichardo-Ontiveros E, Palacios-González B, Vigil-Martínez A, Granados-Portillo O, Guizar-Heredia R, Flores-López A, Medina-Vera I, Heredia-G-Cantón PK, Hernández-Gómez KG, Castelán-Licona G, Arteaga-Sánchez L, Serralde-Zúñiga AE, Ávila-Nava A, Noriega-López LG, Reyes-García JG, Zerrweck C, Torres N, Tovar AR, Guevara-Cruz M. Effect of the intake of dietary protein on insulin resistance in subjects with obesity: a randomized controlled clinical trial. Eur J Nutr. 2021 Aug;60(5):2435-2447. doi: 10.1007/s00394-020-02428-5. Epub 2020 Nov 3. PMID: 33145643.
- Barrea L, Marzullo P, Muscogiuri G, Di Somma C, Scacchi M, Orio F, Aimaretti G, Colao A, Savastano S. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr Res Rev. 2018 Dec;31(2):291-301. doi: 10.1017/S0954422418000136. Epub 2018 Jul 23. PMID: 30033891.
- Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Am J Clin Nutr. 2007 Mar;85(3):688-94. doi: 10.1093/ajcn/85.3.688. PMID: 17344488.
- Karakas SE. Reactive Hypoglycemia: A Trigger for Nutrient-Induced Endocrine and Metabolic Responses in Polycystic Ovary Syndrome. J Clin Med. 2023 Nov 23;12(23):7252. doi: 10.3390/jcm12237252. PMID: 38068304; PMCID: PMC10707371.
- Simon SL, Phimphasone-Brady P, McKenney KM, Gulley LD, Bonny AE, Moore JM, Torres-Zegarra C, Cree MG. Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood. Lancet Child Adolesc Health. 2024 Jun;8(6):443-455. doi: 10.1016/S2352-4642(24)00019-1. Epub 2024 Mar 27. PMID: 38552655; PMCID: PMC11837223.
- Forslund M, Melin J, Alesi S, et al. Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: a systematic review. Clin Endocrinol (Oxf). 2023;99:79-91. doi:10.1111/cen.14913
- Maria Forslund, Johanna Melin, Simon Alesi, Terhi Piltonen, Daniela Romualdi, Chau Thien Tay, Selma Witchel, Alexia Pena, Aya Mousa, Helena Teede, Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis, European Journal of Endocrinology, Volume 189, Issue 1, July 2023, Pages S1–S16, https://doi.org/10.1093/ejendo/lvad082
- Kathryn A Martin, R Rox Anderson, R Jeffrey Chang, David A Ehrmann, Rogerio A Lobo, M Hassan Murad, Michel M Pugeat, Robert L Rosenfield, Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 4, April 2018, Pages 1233–1257, https://doi.org/10.1210/jc.2018-00241
- Diterlizzi, A., Tropea, A., De Luca, E. et al. Use of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome. Arch Gynecol Obstet 312, 1773–1779 (2025). https://doi.org/10.1007/s00404-025-08083-7
- Williams, T., Moore, J. B., & Regehr, J. (2023). Polycystic ovary syndrome: Common questions and answers. American Family Physician.
- ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics & Gynecology 131(6):p e157-e171, June 2018. | DOI: 10.1097/AOG.0000000000002656
- Saadati S, Mason T, Godini R, Vanky E, Teede H, Mousa A. Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges. Diabetes Obes Metab. 2025;27(Suppl. 3):31-47. doi:10.1111/dom.16422
- Cowan S, Lim S, Alycia C, Pirotta S, Thomson R, Gibson-Helm M, Blackmore R, Naderpoor N, Bennett C, Ee C, Rao V, Mousa A, Alesi S, Moran L. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr Disord. 2023 Jan 16;23(1):14. doi: 10.1186/s12902-022-01208-y. PMID: 36647089; PMCID: PMC9841505.
- Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-2469. doi: 10.1210/clinem/dgad463. PMID: 37580314; PMCID: PMC10505534.
- Silverii GA. Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. Diabetes Obes Metab. 2024;26(Suppl. 3):42-54. doi:10.1111/dom.15749
- Teede H, Tassone EC, Piltonen T, et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019;91:479–489. https://doi.org/10.1111/cen.14013
- Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2020, Issue 8. Art. No.: CD005552. DOI: 10.1002/14651858.CD005552.pub3.
- Alpañés M, Álvarez-Blasco F, Fernández-Durán E, Luque-Ramírez M, Escobar-Morreale HF. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. Eur J Endocrinol. 2017 Nov;177(5):399-408. doi: 10.1530/EJE-17-0516. PMID: 28912358.
- Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025 May 13;15(1):16512. doi: 10.1038/s41598-025-99622-4. PMID: 40360648; PMCID: PMC12075827.
- Hakim J, Rajesh D, Tello JA. Neonatal and obstetric outcomes following periconceptional exposure to glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Am J Obstet Gynecol. 2026 Apr 28:S0002-9378(26)00222-X. doi: 10.1016/j.ajog.2026.04.037. Epub ahead of print. PMID: 42061782.
- Simon Alesi, Carolyn Ee, Lisa J Moran, Vibhuti Rao, Aya Mousa,Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome,Advances in Nutrition,Volume 13, Issue 4,2022,Pages 1243-1266,ISSN 2161-8313, https://doi.org/10.1093/advances/nmab141.
- Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647-658. Retrieved Jul 1, 2026, from https://doi.org/10.1530/EC-17-0243
- Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirády P, Ács N, Várbíró S, Horváth EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023 Jan 26;21(1):10. doi: 10.1186/s12958-023-01055-z. PMID: 36703143; PMCID: PMC9878965.
- Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019 Oct;98(10):1235-1244. doi: 10.1111/aogs.13625. Epub 2019 May 20. PMID: 30993683.
- Cesareo R, Attanasio R, Caputo M, Castello R, Chiodini I, Falchetti A, Guglielmi R, Papini E, Santonati A, Scillitani A, Toscano V, Triggiani V, Vescini F, Zini M; AME and Italian AACE Chapter. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients. 2018 Apr 27;10(5):546. doi: 10.3390/nu10050546. PMID: 29702603; PMCID: PMC5986426.
- Walford H, Tyler B, Abbara A, Clarke S, Talaulikar V, Wattar BA. Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews. Clin Endocrinol (Oxf). 2024;101:535-548. doi:10.1111/cen.15101
- Maktabi, M.; Chamani, M.; Asemi, Z. The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Horm. Metab. Res. 2017, 49, 493–498.
- Yang, K., Zeng, L., Bao, T. et al. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 16, 27 (2018). https://doi.org/10.1186/s12958-018-0346-x
- Albardan, L., Platat, C., & Kalupahana, N. S. (2024). Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome. Nutrients, 16(17), 2961. https://doi.org/10.3390/nu16172961
- F Hajizadeh-Sharafabad, J Moludi, H Tutunchi, E Taheri, A Izadi, V Maleki. Selenium and polycystic ovary syndrome; current knowledge and future directions: a systematic review. Horm Metab Res, 51 (05) (2019), pp. 279-287
- Talari, H.R.; Azad, Z.J.; Hamidian, Y.; Samimi, M.; Gilasi, H.R.; Afshar, F.E.; Ostadmohammadi, V.; Asemi, Z. Effects of Carnitine Administration on Carotid Intima-Media Thickness and Inflammatory Factors in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Int. J. Prev. Med. 2019, 10, 89.
- Salehpour S, Nazari L, Hoseini S, Moghaddam PB, Gachkar L. Effects of L-carnitine on Polycystic Ovary Syndrome. JBRA Assist Reprod. 2019 Oct 14;23(4):392-395. doi: 10.5935/1518-0557.20190033. PMID: 31294953; PMCID: PMC6798588.
- Hu X, Wang W, Su X, Peng H, Tan Z, Li Y, Huang Y. Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: a systematic review and network meta-analysis. PeerJ. 2023 Nov 13;11:e16410. doi: 10.7717/peerj.16410. PMID: 38025704; PMCID: PMC10652859.
- Thakker, Divyesh, Raval, Amit, Patel, Isha, Walia, Rama, N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials, Obstetrics and Gynecology International, 2015, 817849, 13 pages, 2015. https://doi.org/10.1155/2015/817849
- Jamilian, M.; Foroozanfard, F.; Mirhosseini, N.; Kavossian, E.; Aghadavod, E.; Bahmani, F.; Ostadmohammadi, V.; Kia, M.; Eftekhar, T.; Ayati, E.; et al. Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome. Front. Endocrinol. 2019, 10, 273.
- Siavash Fazelian, Mohamad H. Rouhani, Sahar Saraf Bank, Reza Amani,Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis,Journal of Trace Elements in Medicine and Biology,Volume 42,2017,Pages 92-96,ISSN
- Zhao G, Fan Y, Li R, Huang Y, Li W, Zhao Y, Zhou M, He J. The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2025 Jul 3;23(1):94. doi: 10.1186/s12958-025-01409-9. PMID: 40611279; PMCID: PMC12224500.0946-672X,https://doi.org/10.1016/j.jtemb.2017.04.008.
- Chen, J., Guo, Q., Pei, Yh. et al. Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study. BMC Women’s Health 20, 69 (2020). https://doi.org/10.1186/s12905-020-00930-w
- Cheshmeh, S.; Elahi, N.; Ghayyem, M.; Mosaieby, E.; Moradi, S.; Pasdar, Y.; Tahmasebi, S.; Moradinazar, M. Effect of Green Cardamom on the Expression of Genes Implicated in Obesity and Diabetes among Obese Women with Polycystic Ovary Syndrome: A Double Blind Randomized Controlled Trial. Genes Nutr. 2022, 17, 17.
- Z Esmaeilinezhad, R Barati-Boldaji, NR Brett, JOT de Zepetnek, N Bellissimo, S Babajafari, Z Sohrabi. The effect of synbiotics pomegranate juice on cardiovascular risk factors in PCOS patients: a randomized, triple-blinded, controlled trial. J Endocrinol Invest, 43 (4) (2020), pp. 539-548
- Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA. 2021;326(1):65–76. doi:10.1001/jama.2021.4788
- Legro, R. S., Brzyski, R. G., Diamond, M. P., et al. (2014). Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine, 371(2), 119–129. https://doi.org/10.1056/nejmoa1313517




Leave a Reply